Dual antiplatelet therapy unmasks distinct platelet reactivity in patients with coronary artery disease.

摘要: Summary. Background: Platelet-induced thrombosis is a major risk factor for recurrent ischemic events, although platelet function in patients with cardiovascular disease taking aspirin and clopidogrel very poorly characterized. The aim of this study was to assess reactivity clopidogrel. Methods: We developed rapid assay measure aggregation response arachidonic acid, collagen, adenosine diphosphate (ADP), epinephrine thrombin receptor activating peptide (TRAP) 80 healthy volunteers. then recruited 200 consecutive from outpatient clinics the cardiac catheterization laboratory tested function. Platelet induced by marker global reactivity. 146 compliant antiplatelet therapy. divided into quartiles. other agonists analysed based on epinephrine. Results: increased significantly across quartiles volunteers (P < 0.0001). A significant increase seen all (P < 0.001). In contrast, only ADP Hypertension, smoking diabetes were associated increasing (P < 0.05). Conclusion: This shows that differs between dual disease, therapy unmasks distinct type but not agonists.